Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05501002 · ClinicalTrials.gov registry record · NA
Pilot Study to Evaluate the CereVasc® EShunt® System in the Treatment of Communicating Hydrocephalus
A NA study, sponsored by CereVasc.
- Terminated
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT05501002 is a NA study that was terminated before completion, run by CereVasc. The registered enrollment target is 4 participants.
The verdict
NCT05501002, a NA study, was terminated before completion, sponsored by CereVasc.
- TERMINATED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study will be to evaluate a novel, minimally invasive method of treating hydrocephalus in adults. The eShunt® System includes a proprietary eShunt® Delivery System and the eShunt® Implant, a permanent implant that is deployed in a mildly invasive, neuro-interventional procedure. The eShunt® Implant is designed to drain excess cerebrospinal fluid (CSF) from the intracranial subarachnoid space (SAS) into the venous system.
Interventions
- DEVICE eShunt® Implant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2022-09-15 |
| Est. Completion | 2023-09-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05501002
The ClinicalTrials.gov registry entry for NCT05501002 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CereVasc, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which eShunt® Implant is the first listed.
NCT05501002 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05501002 about?
NCT05501002 is a clinical study titled "Pilot Study to Evaluate the CereVasc® EShunt® System in the Treatment of Communicating Hydrocephalus". The purpose of this study will be to evaluate a novel, minimally invasive method of treating hydrocephalus in adults. The eShunt® System includes a proprietary eShunt® Delivery System and the eShunt® Implant, a permanent implant that is deployed in a mildly invasive, neuro-interventional procedure. ...
What is the current status of trial NCT05501002?
This trial is currently terminated. It is a NA study. The enrollment target is 4 participants. The study started on 2022-09-15. Estimated completion is 2023-09-15.
What interventions are being tested in trial NCT05501002?
The interventions under investigation include: eShunt® Implant (DEVICE).
Who is sponsoring clinical trial NCT05501002?
This trial is sponsored by CereVasc, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.